View Financial HealthClaritas Pharmaceuticals 配当と自社株買い配当金 基準チェック /06Claritas Pharmaceuticals配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 05Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and InjuriesClaritas Pharmaceuticals, Inc. outlined the Company’s plans for developing R-107, the Company’s nitric oxide-releasing compound, for multiple clinical indications. Phase 1 Study in First Quarter 2022: The first step is completion of their Phase 1 clinical study to demonstrate that R-107 is safe in humans. They expect to complete this study during First Quarter this year. Multiple Phase 2 Studies in 2H 2022: Following completion of the Phase 1 study, they will initiate several Phase 2 clinical studies across multiple clinical indications, as follows: COVID-Related Sepsis: Sepsis is the leading cause of death among COVID-19 patients, and, as they previously announced, a peer-reviewed article was recently published in Scientific Reports disclosing that R-107 effectively preserved multi-organ function in a sheep model of sepsis. These results suggest that R-107 could be a potentially revolutionary new treatment for sepsis. Based on these results, Claritas will initiate a Phase 2 clinical study to evaluate R-107 as a treatment for COVID-related sepsis and will apply for U.S. governmental grant funding to cover the costs of this study. The costs of the preclinical development of R-107 were covered by approximately USD $20 million of grant funding previously provided through the U.S. Department of Health and Human Services, and Claritas will again seek such funding for the costs of this Phase 2 study as well as the potential follow-on Phase 3 study. The worldwide market for treatment of sepsis was valued at more than USD $600 million in 2020 and is projected to grow to USD $1.6 billion by 2031. COVID-Related ARDS: Acute respiratory distress syndrome ("ARDS") is one of thecommon clinical manifestations of severe COVID-19. As they previously announced, a published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust 2 reported that inhaled nitric oxide significantly improved oxygen levels in patients with severe COVID-related ARDS. They believe that these data validate the potential of R-107 as a therapy for COVID-related ARDS, and, in Q3-Q4 2022, they will initiate a Phase 2 clinical study to evaluate R-107 as a treatment for COVID-related ARDS. They will apply for U.S. governmental grant funding to cover the costs of this study, as well as the potential follow-on Phase 3 study. According to an analysis by Reports and Data, the global ARDS market was valued at USD 583.8 million in 2018 and is expected to reach USD 934.8 million by the year 2026. PAH: Pulmonary arterial hypertension ("PAH") is a lethal condition, with no cure, resulting from high blood pressure in the lungs. The worldwide market for treatment of PAH exceeds $6 billion per year and is projected to grow to $9.8 billion by 20273. As they previously announced, R-107 is the first and only drug to demonstrate a durable reversal of established disease in a validated animal model of PAH. The data from this study are unprecedented in the scientific literature and suggest that R-107 is a potentially revolutionary new treatment for PAH. Claritas will initiate a Phase 2a clinical study of R-107 in hospitalized patients with PAH by mid-2022, which they expect to complete during Fourth Quarter 2022.お知らせ • Feb 27Kalytera Therapeutics, Inc. Launches New WebsiteKalytera Therapeutics, Inc. announced the launch of its new website.お知らせ • Feb 26Kalytera Therapeutics' Listing to Transfer from TSXV Tier 1 to Tier 2The TSX Venture Exchange (TSXV) determined that Kalytera Therapeutics, Inc. has not maintained its Tier 1 Continued Listing Requirements. The Company will therefore be transferred from Tier 1 to Tier 2 in conjunction with its reinstatement to trade.決済の安定と成長配当データの取得安定した配当: CLAZ.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CLAZ.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Claritas Pharmaceuticals 配当利回り対市場CLAZ.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CLAZ.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.0%アナリスト予想 (CLAZ.F) (最長3年)n/a注目すべき配当: CLAZ.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CLAZ.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CLAZ.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CLAZ.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 01:20終値2026/02/27 00:00収益2021/09/30年間収益2020/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Claritas Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 05Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and InjuriesClaritas Pharmaceuticals, Inc. outlined the Company’s plans for developing R-107, the Company’s nitric oxide-releasing compound, for multiple clinical indications. Phase 1 Study in First Quarter 2022: The first step is completion of their Phase 1 clinical study to demonstrate that R-107 is safe in humans. They expect to complete this study during First Quarter this year. Multiple Phase 2 Studies in 2H 2022: Following completion of the Phase 1 study, they will initiate several Phase 2 clinical studies across multiple clinical indications, as follows: COVID-Related Sepsis: Sepsis is the leading cause of death among COVID-19 patients, and, as they previously announced, a peer-reviewed article was recently published in Scientific Reports disclosing that R-107 effectively preserved multi-organ function in a sheep model of sepsis. These results suggest that R-107 could be a potentially revolutionary new treatment for sepsis. Based on these results, Claritas will initiate a Phase 2 clinical study to evaluate R-107 as a treatment for COVID-related sepsis and will apply for U.S. governmental grant funding to cover the costs of this study. The costs of the preclinical development of R-107 were covered by approximately USD $20 million of grant funding previously provided through the U.S. Department of Health and Human Services, and Claritas will again seek such funding for the costs of this Phase 2 study as well as the potential follow-on Phase 3 study. The worldwide market for treatment of sepsis was valued at more than USD $600 million in 2020 and is projected to grow to USD $1.6 billion by 2031. COVID-Related ARDS: Acute respiratory distress syndrome ("ARDS") is one of thecommon clinical manifestations of severe COVID-19. As they previously announced, a published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust 2 reported that inhaled nitric oxide significantly improved oxygen levels in patients with severe COVID-related ARDS. They believe that these data validate the potential of R-107 as a therapy for COVID-related ARDS, and, in Q3-Q4 2022, they will initiate a Phase 2 clinical study to evaluate R-107 as a treatment for COVID-related ARDS. They will apply for U.S. governmental grant funding to cover the costs of this study, as well as the potential follow-on Phase 3 study. According to an analysis by Reports and Data, the global ARDS market was valued at USD 583.8 million in 2018 and is expected to reach USD 934.8 million by the year 2026. PAH: Pulmonary arterial hypertension ("PAH") is a lethal condition, with no cure, resulting from high blood pressure in the lungs. The worldwide market for treatment of PAH exceeds $6 billion per year and is projected to grow to $9.8 billion by 20273. As they previously announced, R-107 is the first and only drug to demonstrate a durable reversal of established disease in a validated animal model of PAH. The data from this study are unprecedented in the scientific literature and suggest that R-107 is a potentially revolutionary new treatment for PAH. Claritas will initiate a Phase 2a clinical study of R-107 in hospitalized patients with PAH by mid-2022, which they expect to complete during Fourth Quarter 2022.
お知らせ • Feb 27Kalytera Therapeutics, Inc. Launches New WebsiteKalytera Therapeutics, Inc. announced the launch of its new website.
お知らせ • Feb 26Kalytera Therapeutics' Listing to Transfer from TSXV Tier 1 to Tier 2The TSX Venture Exchange (TSXV) determined that Kalytera Therapeutics, Inc. has not maintained its Tier 1 Continued Listing Requirements. The Company will therefore be transferred from Tier 1 to Tier 2 in conjunction with its reinstatement to trade.